ZNF687 Inhibitors
ZNF687 inhibitors encompass a diverse array of chemical compounds designed to indirectly suppress the functional activity of ZNF687 by targeting specific cell signaling pathways. PD 98059 and U0126, both MEK inhibitors, effectively block the MAPK/ERK pathway, which is responsible for a wide range of cellular functions, including cell cycle progression and differentiation. Inhibition of this pathway is likely to result in a reduction of ZNF687 activity, assuming ZNF687 is regulated by or associated with this pathway. Likewise, the PI3K inhibitors LY 294002 and Wortmannin lead to attenuated AKT phosphorylation and downstream signaling, which can be critical for processes that ZNF687 might influence, thus restraining ZNF687's functional activity. Rapamycin, an mTOR inhibitor, and Y-27632, a ROCK inhibitor, further contribute to the inhibition by targeting protein synthesis and cytoskeletal organization respectively, processes which might be essential for the proper functioning of ZNF687.
The inhibitory effects extend to other pathways with compounds like SB 203580, a p38 MAPK inhibitor, and SP600125, a JNK inhibitor, which modulate the MAPK signaling axis and could, in turn, reduce ZNF687 activity if there is a regulatory connection. Dasatinib, by targeting Src family kinases, could disrupt signaling pathways that might activate ZNF687, hence leading to its inhibition. GSK-3 Inhibitor XVI, by inhibiting GSK-3, could lead to the accumulation of β-catenin, a process which, if negatively correlated with ZNF687 activity, would result in its inhibition. Tyrphostin B42, a JAK2 inhibitor, and Bisindolylmaleimide I, a PKC inhibitor, further demonstrate the capacity to impede ZNF687 activity by targeting the JAK/STAT and PKC pathways, respectively, both of which could have implications for the regulation and function of ZNF687. Collectively, these inhibitors provide a comprehensive approach to diminishing the functional activity of ZNF687 through a multi-pathway strategy, although they do so indirectly by interfacing with pathways that ZNF687 is presumed to be a part of or regulated by.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD 98059 is a selective MEK inhibitor that blocks the MAPK/ERK pathway. ZNF687 can be indirectly inhibited by PD 98059, as the MAPK/ERK pathway may be involved in the regulatory network affecting ZNF687 activity, leading to diminished functional activity of ZNF687. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY 294002 is a phosphoinositide 3-kinase (PI3K) inhibitor. By inhibiting PI3K, it leads to a decrease in AKT phosphorylation, which is crucial for many cellular processes. ZNF687, if influenced by PI3K/AKT pathway signaling, would experience decreased activity due to reduced downstream signaling. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor that interferes with the mTORC1 pathway, which is implicated in protein synthesis and cell growth. By inhibiting this pathway, Rapamycin can indirectly lead to decreased activity of ZNF687 if ZNF687 is downstream or affected by mTOR signaling. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is a ROCK inhibitor, it diminishes the Rho/ROCK pathway activity, which plays a significant role in actin cytoskeleton organization. If ZNF687 is involved in cytoskeleton-dependent processes, Y-27632 would result in diminished ZNF687 activity by altering the cytoskeleton dynamics. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAPK. This inhibition can lead to altered transcription factor activation, potentially diminishing ZNF687 activity if it is regulated by or dependent on the p38 MAPK pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent PI3K inhibitor that can diminish AKT signaling. If ZNF687 activity is modulated by PI3K/AKT pathway, Wortmannin's action would lead to a decrease in ZNF687 functional activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a MEK inhibitor that can diminish ERK pathway signaling. If the ERK pathway regulates ZNF687 or if ZNF687 is a part of the ERK pathway regulatory network, then U0126 will lead to reduced ZNF687 activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, another MAPK pathway component. By inhibiting JNK signaling, SP600125 could decrease ZNF687 activity if ZNF687 is modulated by the JNK pathway. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a Src family kinase inhibitor. By inhibiting Src kinases, Dasatinib could lead to diminished ZNF687 activity if ZNF687 is involved in signaling pathways regulated by Src family kinases. | ||||||
GSK-3 Inhibitor XVI | 252917-06-9 | sc-221691 sc-221691A | 5 mg 25 mg | $153.00 $520.00 | 4 | |
GSK-3 Inhibitor XVI is a GSK-3 inhibitor. By inhibiting GSK-3, it can lead to the stabilization and accumulation of β-catenin, which may result in decreased activity of ZNF687 if ZNF687 is negatively regulated by β-catenin signaling. | ||||||